Avandamet

Land: Evrópusambandið

Tungumál: enska

Heimild: EMA (European Medicines Agency)

Kauptu það núna

Download Vara einkenni (SPC)
08-06-2016
Download Opinber matsskýrsla (PAR)
08-06-2016

Virkt innihaldsefni:

rosiglitazone, metformin hydrochloride

Fáanlegur frá:

SmithKline Beecham Plc

ATC númer:

A10BD03

INN (Alþjóðlegt nafn):

rosiglitazone, metformin

Meðferðarhópur:

Drugs used in diabetes

Lækningarsvæði:

Diabetes Mellitus, Type 2

Ábendingar:

AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

Vörulýsing:

Revision: 16

Leyfisstaða:

Withdrawn

Leyfisdagur:

2003-10-20

Upplýsingar fylgiseðill

                                Medicinal product no longer authorised
105
B. PACKAGE LEAFLET
Medicinal product no longer authorised
106
PACKAGE LEAFLET: INFORMATION FOR THE USER
AVANDAMET 1 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/500 MG FILM-COATED TABLETS
AVANDAMET 2 MG/1000 MG FILM-COATED TABLETS
AVANDAMET 4 MG/1000 MG FILM-COATED TABLETS
rosiglitazone/metformin HCl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE.
-
KEEP THIS LEAFLET. YOU MAY NEED TO READ IT AGAIN.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even
if their symptoms are the same as yours.
-
IF ANY OF THE SIDE EFFECTS GETS SERIOUS, OR IF YOU NOTICE ANY SIDE
EFFECTS NOT LISTED IN THIS
LEAFLET, TELL YOUR DOCTOR OR PHARMACIST.
IN THIS LEAFLET
:
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
2.
BEFORE YOU TAKE AVANDAMET
3.
HOW TO TAKE AVANDAMET
4.
POSSIBLE SIDE EFFECTS
5
HOW TO STORE AVANDAMET
6.
FURTHER INFORMATION
1.
WHAT AVANDAMET IS AND WHAT IT IS USED FOR
AVANDAMET TABLETS ARE A COMBINATION OF TWO DIFFERENT MEDICINES
called
_rosiglitazone_
and
_metformin. _
These two medicines are used to treat
TYPE 2 DIABETES.
People with type 2 diabetes either don’t make enough insulin (a
hormone that controls blood sugar
levels), or don’t respond normally to the insulin their body makes.
Rosiglitazone and metformin work
together so your body makes better use of the insulin it produces, and
this helps reduce your blood
sugar to a normal level. Avandamet can be used alone or with a
sulphonylurea, another medicine for
diabetes.
2.
BEFORE YOU TAKE AVANDAMET
To help manage your diabetes, it is important that you follow any diet
and lifestyle advice from your
doctor as well as taking Avandamet.
DON’T TAKE AVANDAMET:
•
IF YOU ARE ALLERGIC
(
_hypersensitive_
) to rosiglitazone or metformin or any of the other
ingredients of Avandamet (
_listed in Section 6)_
•
IF YOU HAVE HAD A HEART ATTACK OR SEVERE ANGINA,
that’s being treated in hospital
•

                                
                                Lestu allt skjalið
                                
                            

Vara einkenni

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
AVANDAMET 1 mg/500 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
_ _
Each tablet contains 1 mg of rosiglitazone (as rosiglitazone maleate)
and 500 mg of metformin
hydrochloride (corresponding to metformin free base 390 mg).
Excipients:
Each tablet contains lactose (approximately 6 mg).
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet.
Yellow film-coated tablets marked "gsk" on one side and "1/500" on the
other.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
AVANDAMET is indicated in the treatment of type 2 diabetes mellitus
patients, particularly
overweight patients:
-
who are unable to achieve sufficient glycaemic control at their
maximally tolerated dose of oral
metformin alone.
-
in triple oral therapy with sulphonylurea in patients with
insufficient glycaemic control despite
dual oral therapy with their maximally tolerated dose of metformin and
a sulphonylurea (see
section 4.4).
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
The usual starting dose of AVANDAMET is 4 mg/day rosiglitazone plus
2000 mg/day metformin
hydrochloride.
Rosiglitazone can be increased to 8 mg/day after 8 weeks if greater
glycaemic control is required. The
maximum recommended daily dose of AVANDAMET is 8 mg rosiglitazone plus
2000 mg metformin
hydrochloride.
The total daily dose of AVANDAMET should be given in two divided
doses.
Dose titration with rosiglitazone (added to the optimal dose of
metformin) may be considered before
the patient is switched to AVANDAMET.
When clinically appropriate, direct change from metformin monotherapy
to AVANDAMET may be
considered.
Taking AVANDAMET with or just after food may reduce gastrointestinal
symptoms associated with
metformin.
Triple oral therapy (rosiglitazone, metformin and sulphonylurea) (see
section 4.4)
Medicinal product no longer authorised
3
-
Patients on metformin and sulp
                                
                                Lestu allt skjalið
                                
                            

Skjöl á öðrum tungumálum

Upplýsingar fylgiseðill Upplýsingar fylgiseðill búlgarska 08-06-2016
Vara einkenni Vara einkenni búlgarska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla búlgarska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill spænska 08-06-2016
Vara einkenni Vara einkenni spænska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla spænska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill tékkneska 08-06-2016
Vara einkenni Vara einkenni tékkneska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla tékkneska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill danska 08-06-2016
Vara einkenni Vara einkenni danska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla danska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill þýska 08-06-2016
Vara einkenni Vara einkenni þýska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla þýska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill eistneska 08-06-2016
Vara einkenni Vara einkenni eistneska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla eistneska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill gríska 08-06-2016
Vara einkenni Vara einkenni gríska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla gríska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill franska 08-06-2016
Vara einkenni Vara einkenni franska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla franska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ítalska 08-06-2016
Vara einkenni Vara einkenni ítalska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla ítalska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill lettneska 08-06-2016
Vara einkenni Vara einkenni lettneska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla lettneska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill litháíska 08-06-2016
Vara einkenni Vara einkenni litháíska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla litháíska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill ungverska 08-06-2016
Vara einkenni Vara einkenni ungverska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla ungverska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill maltneska 08-06-2016
Vara einkenni Vara einkenni maltneska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla maltneska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill hollenska 08-06-2016
Vara einkenni Vara einkenni hollenska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla hollenska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill pólska 08-06-2016
Vara einkenni Vara einkenni pólska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla pólska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill portúgalska 08-06-2016
Vara einkenni Vara einkenni portúgalska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla portúgalska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill rúmenska 08-06-2016
Vara einkenni Vara einkenni rúmenska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla rúmenska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvakíska 08-06-2016
Vara einkenni Vara einkenni slóvakíska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla slóvakíska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill slóvenska 08-06-2016
Vara einkenni Vara einkenni slóvenska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla slóvenska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill finnska 08-06-2016
Vara einkenni Vara einkenni finnska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla finnska 08-06-2016
Upplýsingar fylgiseðill Upplýsingar fylgiseðill sænska 08-06-2016
Vara einkenni Vara einkenni sænska 08-06-2016
Opinber matsskýrsla Opinber matsskýrsla sænska 08-06-2016

Leitaðu viðvaranir sem tengjast þessari vöru

Skoða skjalasögu